Association Between Noninvasive Liver Fibrosis Scores and Heart Failure in a General Population

Background The association between nonalcoholic fatty liver disease and cardiovascular disease is firmly established, yet the association between noninvasive liver fibrosis scores and cardiovascular events remains a topic of uncertainty. Our study aimed to explore the association between liver fibrosis and heart failure. Methods and Results The data set was from the National Health and Nutrition Examination Survey 2011 to 2018. Advanced hepatic fibrosis risk was assessed through 3 noninvasive liver fibrosis scores: Fibrosis‐4 score (FIB‐4), the nonalcoholic fatty liver disease fibrosis score (NFS), and the aspartate aminotransferase to platelet ratio index (APRI). We included 19 695 eligible participants. The national prevalence of advanced liver fibrosis risk in the United States was 4.20%, 8.06%, and 0.35% as determined by FIB‐4, NFS, and APRI scores, respectively. Weighted logistic regression analysis revealed significant associations between advanced liver fibrosis risk and the prevalence of heart failure (continuous variables, FIB‐4: odds ratio [OR], 1.15 [95% CI, 1.07–1.23]; NFS: OR, 1.42 [95% CI, 1.23–1.64]; APRI: OR, 1.44 [95% CI, 1.15–1.81]). When the scores were assessed as categorical variables, the results were still significant (FIB‐4 ≥2.67 versus FIB‐4 <1.3: OR, 2.18 [95% CI, 1.47–3.24]; NFS ≥0.675 versus NFS <−1.455: OR, 2.53 [95% CI, 1.37–4.68]). Subgroup analysis found that the association between APRI and heart failure was stronger in female patients. Conclusions In the general US population, the prevalence of advanced liver fibrosis risk varied between 0.35% and 8.06% as indicated by noninvasive liver fibrosis scores. FIB‐4, NFS, and APRI scores were linked to an elevated prevalence of heart failure.